RBF Protein with MA103 Adjuvant Elicited Protective Immunity against Human Respiratory Syncytial Virus in BALB/c Mice

Qiongqiong Fang(Beijing Center for Disease Prevention and Control), Wenbo Xu(Shenyang Institute of Automation), Hu Ren(National Institute for Viral Disease Control and Prevention), Hai Li(Shanghai East Hospital), Yan Zhang(Memorial Sloan Kettering Cancer Center), Lei Cao(Chinese Academy of Sciences), Hongqiao Hu(National Institute for Viral Disease Control and Prevention)
Japanese Journal of Infectious Diseases
January 30, 2023
10.7883/yoken.jjid.2022.476
Cited by 0

Related Papers

A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China
|Virology Journal|2010|473